CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...